Cargando…

CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT

CD155 is a shared ligand for activating and inhibitory immunoreceptors DNAX accessory molecule 1 (DNAM‐1), also called CD226, and T cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif domain (TIGIT), which are expressed on natural killer (NK) cells and T cells, and positively and...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuo, Tomohei, Iguchi‐Manaka, Akiko, Shibuya, Akira, Shibuya, Kazuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633295/
https://www.ncbi.nlm.nih.gov/pubmed/35947095
http://dx.doi.org/10.1111/cas.15526
_version_ 1784824233171353600
author Matsuo, Tomohei
Iguchi‐Manaka, Akiko
Shibuya, Akira
Shibuya, Kazuko
author_facet Matsuo, Tomohei
Iguchi‐Manaka, Akiko
Shibuya, Akira
Shibuya, Kazuko
author_sort Matsuo, Tomohei
collection PubMed
description CD155 is a shared ligand for activating and inhibitory immunoreceptors DNAX accessory molecule 1 (DNAM‐1), also called CD226, and T cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif domain (TIGIT), which are expressed on natural killer (NK) cells and T cells, and positively and negatively regulates tumor immune responses, respectively. A recent study showed that the single nucleotide polymorphism rs1058402G>A causing a mutation to Thr from Ala at residue 67 of CD155 is associated with worse overall survival of patients with small cell lung cancer and suggested that this is caused by the decreased affinity of mutant CD155 for DNAM‐1 as a result of the 3D structural analysis. Unexpectedly, however, we found that the mutation increased the binding affinity for TIGIT rather than decreased the binding affinity for DNAM‐1 and induced a stronger signal than WT CD155. Our results suggest that the mutation suppresses tumor immune responses by generating a stronger inhibitory signal in immune cells in the tumor microenvironment.
format Online
Article
Text
id pubmed-9633295
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-96332952022-11-07 CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT Matsuo, Tomohei Iguchi‐Manaka, Akiko Shibuya, Akira Shibuya, Kazuko Cancer Sci Reports CD155 is a shared ligand for activating and inhibitory immunoreceptors DNAX accessory molecule 1 (DNAM‐1), also called CD226, and T cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif domain (TIGIT), which are expressed on natural killer (NK) cells and T cells, and positively and negatively regulates tumor immune responses, respectively. A recent study showed that the single nucleotide polymorphism rs1058402G>A causing a mutation to Thr from Ala at residue 67 of CD155 is associated with worse overall survival of patients with small cell lung cancer and suggested that this is caused by the decreased affinity of mutant CD155 for DNAM‐1 as a result of the 3D structural analysis. Unexpectedly, however, we found that the mutation increased the binding affinity for TIGIT rather than decreased the binding affinity for DNAM‐1 and induced a stronger signal than WT CD155. Our results suggest that the mutation suppresses tumor immune responses by generating a stronger inhibitory signal in immune cells in the tumor microenvironment. John Wiley and Sons Inc. 2022-08-30 2022-11 /pmc/articles/PMC9633295/ /pubmed/35947095 http://dx.doi.org/10.1111/cas.15526 Text en © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Reports
Matsuo, Tomohei
Iguchi‐Manaka, Akiko
Shibuya, Akira
Shibuya, Kazuko
CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT
title CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT
title_full CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT
title_fullStr CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT
title_full_unstemmed CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT
title_short CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT
title_sort cd155 mutation (ala67thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor tigit
topic Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633295/
https://www.ncbi.nlm.nih.gov/pubmed/35947095
http://dx.doi.org/10.1111/cas.15526
work_keys_str_mv AT matsuotomohei cd155mutationala67thrincreasesthebindingaffinityforandthesignalingviaaninhibitoryimmunoreceptortigit
AT iguchimanakaakiko cd155mutationala67thrincreasesthebindingaffinityforandthesignalingviaaninhibitoryimmunoreceptortigit
AT shibuyaakira cd155mutationala67thrincreasesthebindingaffinityforandthesignalingviaaninhibitoryimmunoreceptortigit
AT shibuyakazuko cd155mutationala67thrincreasesthebindingaffinityforandthesignalingviaaninhibitoryimmunoreceptortigit